Skip to content
Back to meeting Original
Yakup Ergün· @dr_yakupergun · X·· 2 days agoScore70

tucatinib

Body

#ESMO26 | BRIDGET

A clinically valuable study addressing a real treatment dilemma in HER2+ breast cancer. Adding tucatinib after local therapy for isolated brain progression achieved 18-month intracranial PFS of 59% and extracranial PFS of 98%.

Durable CNS control while maintaining an effective systemic regimen—a thoughtful strategy with compelling results. Congratulations to the investigators! @drsarahsam 👏

63 views · 2 likes · 1 repost · 0 replies

Conference abstracts
1766ROmatched by Rapid oral 1: Breast cancer, advanced stage

Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC

https://esmocongress.esmo.org

Source: Yakup Ergün · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.